Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Bharat Biotech expands into advanced biologics with Nucelion Therapeutics, a new CRDMO for cell and gene therapy manufacturing, positioning India as a rising hub for global biotherapeutics.

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series B funding that the Italian biotech will use to | Amgen Ventures-backed ...

Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...